CY1113826T1 - Ανοσοενισχυτικα για εμβολια - Google Patents

Ανοσοενισχυτικα για εμβολια

Info

Publication number
CY1113826T1
CY1113826T1 CY20131100210T CY131100210T CY1113826T1 CY 1113826 T1 CY1113826 T1 CY 1113826T1 CY 20131100210 T CY20131100210 T CY 20131100210T CY 131100210 T CY131100210 T CY 131100210T CY 1113826 T1 CY1113826 T1 CY 1113826T1
Authority
CY
Cyprus
Prior art keywords
vaccine
adjuvant
immunosuppressants
vaccines
squalene
Prior art date
Application number
CY20131100210T
Other languages
English (en)
Inventor
Michael Broker
Original Assignee
Novartis Vaccines And Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics Gmbh filed Critical Novartis Vaccines And Diagnostics Gmbh
Publication of CY1113826T1 publication Critical patent/CY1113826T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Εμβόλιο, το οποίο περιέχει ένα πρώτο εμβόλιο ανοσοενισχυμένο με ένα γαλάκτωμα ελαίου σε νερό, το οποίο περιλαμβάνει 5% σκουαλένιο, 0,5 πολυσορβικό 80 και 0,5% τριελαϊκή σορβιτάνη σε υδατικό ρυθμιστικό διάλυμα κιτρικών pH 6,5 και ένα μη ανοσοενισχυμένο δεύτερο εμβόλιο ως ουσία συνδυασμού για ταυτόχρονη, χωριστή ή χρονικά διαβαθμισμένη εφαρμογή για ανοσοποίηση έναντι ιικών, βακτηριακών ή παρασιτικών λοιμωδών νόσων.
CY20131100210T 2000-03-14 2013-03-06 Ανοσοενισχυτικα για εμβολια CY1113826T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10012370A DE10012370A1 (de) 2000-03-14 2000-03-14 Adjuvans für Vakzinen
EP01931522A EP1265633B1 (de) 2000-03-14 2001-03-14 Adjuvans für vakzinen

Publications (1)

Publication Number Publication Date
CY1113826T1 true CY1113826T1 (el) 2016-07-27

Family

ID=7634665

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100210T CY1113826T1 (el) 2000-03-14 2013-03-06 Ανοσοενισχυτικα για εμβολια

Country Status (11)

Country Link
US (2) US20040047882A1 (el)
EP (1) EP1265633B1 (el)
JP (1) JP2003526676A (el)
AU (1) AU2001258279A1 (el)
CA (1) CA2402935A1 (el)
CY (1) CY1113826T1 (el)
DE (1) DE10012370A1 (el)
DK (1) DK1265633T3 (el)
ES (1) ES2398451T3 (el)
PT (1) PT1265633E (el)
WO (1) WO2001068129A2 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1651265T1 (sl) * 2003-07-24 2008-10-31 Merial Ltd Formulacije cepiva, ki obsegajo emulzijo olje v vodi
CA2646349A1 (en) * 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
JP5566687B2 (ja) * 2006-06-15 2014-08-06 ノバルティス アーゲー アジュバントを使用しない複数回投与ワクチン接種レジメン
CA2671629C (en) * 2006-12-06 2017-08-15 Novartis Ag Vaccines including antigen from four strains of influenza virus
RS51999B (en) * 2008-08-28 2012-04-30 Novartis Ag Obtaining squalene from hyperproductive yeasts
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
WO2011066390A2 (en) * 2009-11-25 2011-06-03 Wildcat Discovery Technologies, Inc. Nanoscale adjuvants and related pharmaceutical compositions and methods
EP2575870B1 (en) 2010-06-04 2016-12-07 Wyeth LLC Vaccine formulations
EP2719395A1 (en) 2010-09-01 2014-04-16 Novartis AG Adsorption of immunopotentiators to insoluble metal salts
JP6191082B2 (ja) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム より低用量の抗原および／またはアジュバントを有する混合ワクチン
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
CN102671194B (zh) * 2012-05-07 2013-08-14 成都康华生物制品有限公司 一种人用预防狂犬病和破伤风的疫苗
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CA3033364A1 (en) 2016-09-02 2018-03-08 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN118512582A (zh) 2018-01-02 2024-08-20 克洛里斯生物科学有限公司 作为癌症的预防性和诊疗性治疗的ipsc基疫苗
TWI694254B (zh) * 2018-03-26 2020-05-21 國光生物科技股份有限公司 一種定量疫苗成品劑量方法及試組
CN110680798B (zh) * 2018-07-04 2024-02-09 辽宁成大生物股份有限公司 一种含佐剂mf59和芦荟提取物组合的肺炎多糖疫苗可溶性微针
CN110664749B (zh) * 2019-10-21 2021-07-30 上海市皮肤病医院 一种基于mf59包载抗原纳米乳及其制备方法和应用
EP4333883A2 (en) 2021-05-06 2024-03-13 Hipra Scientific, S.L.U. Sars-cov-2 subunit vaccine
BR112023023094A2 (pt) 2021-05-06 2024-02-06 Hipra Scient S L U Vacina de subunidade de sars-cov-2
JP2024529429A (ja) 2021-06-01 2024-08-06 クロリス・バイオサイエンシーズ・インコーポレイテッド 人工多能性幹細胞に基づくがんワクチン
KR20240082339A (ko) 2021-08-13 2024-06-10 클로리스 바이오사이언시스 인코포레이티드 암에 대한 예방적 및 치료적 치료로서 ipsc-기반 백신

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05294845A (ja) * 1991-11-25 1993-11-09 Nisshin Oil Mills Ltd:The 免疫原組成物
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
DE69836543T2 (de) * 1997-05-01 2007-09-20 Protechtion Unlimited, Inc., Wilmington Nervenwachstumsfaktor als impfstoffadjuvans
AU4973199A (en) * 1998-07-09 2000-02-01 Merck & Co., Inc. Polynucleotide vaccine formulations
EP1144640A3 (en) * 1998-07-27 2001-11-28 Microbial Technics Limited Nucleic acids and proteins from streptococcus pneumoniae
WO2007052155A2 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant

Also Published As

Publication number Publication date
WO2001068129A2 (de) 2001-09-20
PT1265633E (pt) 2013-01-31
ES2398451T3 (es) 2013-03-19
EP1265633B1 (de) 2012-12-12
EP1265633A2 (de) 2002-12-18
CA2402935A1 (en) 2001-09-20
AU2001258279A1 (en) 2001-09-24
US20040047882A1 (en) 2004-03-11
DK1265633T3 (da) 2013-01-07
WO2001068129A3 (de) 2002-03-14
DE10012370A1 (de) 2001-09-27
US20090208523A1 (en) 2009-08-20
JP2003526676A (ja) 2003-09-09

Similar Documents

Publication Publication Date Title
CY1113826T1 (el) Ανοσοενισχυτικα για εμβολια
CY1120574T1 (el) Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
UY26555A1 (es) Composición farmacéutica para modulación inmunológica y preparación de vacunas
CY1110290T1 (el) Εμβολιο χοιρειου κυκλοϊου και κοκκοϊου
DK1163000T3 (da) Vacciner imod antigener fra bakterier
CY1107457T1 (el) Εμβoλιο κατa του hpv
CY1113530T1 (el) Εμβολιο εναντι του αναπαραγωγικου και αναπνευστικου συνδρομου των χοιρων, βασισμενο στο απομονωθεν στελεχος ja-142
AR027680A1 (es) Vacuna contra la salmonella materiales y metodos
CY1113020T1 (el) Εμβολια συνδυασμου για neisseria meningitidis
CY1105389T1 (el) Hpv-e7 ως αγωγη εναντι του ιου θηλωματων ανθρωπου
ATE542829T1 (de) Impfstoff
CY1108526T1 (el) Εμβολια εναντι καρκινων
ATE419873T1 (de) Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
DK1259259T3 (da) Mucosal adjuvansformulering
CY1108178T1 (el) Βακτηριο που προκαλει νοσο των πουλερικων και εμβολιο προερχομενο εξ' αυτου
WO2002010343A3 (en) Temperature-sensitive live vaccine for mycoplasma hyopneumoniae
PT1112747E (pt) Vacina de salmonella que nao induz anticorpos contra flagelina ou flagelos
ATE507286T1 (de) Immunisierung von fischen gegen virusinfektion
EA200400197A1 (ru) Способы получения поливалентных бактериофагов для лечения бактериальных инфекций
ATE543511T1 (de) Attenuierte lebendimpfstoffe gegen pleuropneumonie bei schweinen
ATE310008T1 (de) Immunologische adjuvans verbindungen
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
ATE372129T1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
CO5660272A2 (es) Vacunas bovinas con adyuvantes